Login to Your Account



Pharma License Option Signed

PKAN Logs Retrophin $25M; Autism/Schizo Bid Lies Ahead, Too

By Randy Osborne
Staff Writer

Friday, August 16, 2013
With $25 million pledged from a stock sale to institutional investors, rare-disease specialist Retrophin Inc. signed a deal with an unidentified pharma firm for an option to license its autism/schizophrenia drug and said plans for a potentially pivotal trial are on track for RE-021.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription